(Q33785128)

English

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

29 July 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Timothy P Reilly

1

1 reference

Europe PubMed Central

29 July 2017

Michael J Graziano

2

1 reference

Europe PubMed Central

29 July 2017

Evan B Janovitz

3

1 reference

Europe PubMed Central

29 July 2017

Thomas E Dorr

4

1 reference

Europe PubMed Central

29 July 2017

Craig Fairchild

5

1 reference

Europe PubMed Central

29 July 2017

Francis Lee

6

1 reference

Europe PubMed Central

29 July 2017

Jian Chen

7

1 reference

Europe PubMed Central

29 July 2017

Tai Wong

8

1 reference

Europe PubMed Central

29 July 2017

Jean M Whaley

9

1 reference

Europe PubMed Central

29 July 2017

Mark Tirmenstein

10

1 reference

Europe PubMed Central

29 July 2017

publication date

29 January 2014

1 reference

Europe PubMed Central

29 July 2017

Diabetes Therapy

1 reference

Europe PubMed Central

29 July 2017

5

1 reference

Europe PubMed Central

29 July 2017

1

1 reference

Europe PubMed Central

29 July 2017

73-96

1 reference

Europe PubMed Central

29 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

29 January 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s13300-014-0053-3

0 references

Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Consideration of rat chronic progressive nephropathy in regulatory evaluations for carcinogenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

SGLT-2 inhibitors in development for type 2 diabetes treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Expression of Na+-D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

SGLT2 mediates glucose reabsorption in the early proximal tubule.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Validation of an in vitro screening test for predicting the tumor promoting potential of chemicals based on gene expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Identification of tumor promotion marker genes for predicting tumor promoting potential of chemicals in BALB/c 3T3 cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

A contemporary overview of chronic progressive nephropathy in the laboratory rat, and its significance for human risk assessment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Factors contributory to early death of young CD-1 mice in carcinogenicity studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Status of glucose transporters in the mammalian kidney and renal development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

The aging kidney: insights from experimental studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Phloridzin and phloretin inhibition of 2-deoxy-D-glucose uptake by tumor cells in vitro and in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Congenital polycystic kidney disease. Genetically transmitted infantile polycystic kidney disease in C57BL/6J mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Cancer Of The Urinary Tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Urologic syndrome associated with wire caging in AKR mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Toxicology and carcinogenicity studies of diuretics in F344 rats and B6C3F1 mice. 2. Furosemide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

4 July 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Diabetes increases the risk of breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

A generalized Wilcoxon test for comparing arbitrarily singly-censored samples

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Mortality, major cause of moribundity, and spontaneous tumors in CD-1 mice

1 reference

https://api.crossref.org/works/10.1007%2FS13300-014-0053-3

21 January 2018

Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4065287

30 October 2018

The efficacy of phloridzin and phloretin on tumor cell growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/24474422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES

1 reference

https://pubmed.ncbi.nlm.nih.gov/24474422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24474422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Type 2 diabetes mellitus, insulin-use and risk of bladder cancer in a large cohort study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24474422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cancer cell line

1 reference

https://pubmed.ncbi.nlm.nih.gov/24474422

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S13300-014-0053-3

1 reference

Europe PubMed Central

29 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33785128&oldid=1973968325"